Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 389
Filtrar
1.
Reumatol. clín. (Barc.) ; 16(5,pt.1): 345-352, sept.-oct. 2020. tab, graf
Artigo em Inglês | IBECS | ID: ibc-195891

RESUMO

OBJECTIVES: To assess the effectiveness and safety of certolizumab pegol (CZP) in Spanish patients with RA. MATERIALS AND METHODS: SONAR (NCT01526434), a 12-week, open-label, prospective, observational, multicenter study. Patients with active RA for ≥3 months, according to ACR criteria, were treated with CZP (400mg at Weeks 0, 2 and 4, then 200mg every 2 weeks). The primary effectiveness endpoint was change from baseline (CFB) in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12. Other assessments included DAS28(ESR), patient's assessment of arthritis pain (PtAAP-VAS) and Short Form 36-item Health Survey (SF-36) physical component summary (PCS) and mental component summary (MCS). Joint inflammation was investigated using Power Doppler (PD) ultrasound (US), to detect effusion, synovial hypertrophy and synovial PD signal. PDUS outcomes assessed CFB to Week 12 in synovial hypertrophy, effusion and PD signal indices. RESULTS: A total of 77/80 enrolled patients received ≥1 dose of CZP. The 12-week mean reduction from baseline (SD) was −0.6 (0.6) for HAQ-DI and −2.2 (1.5) for DAS28(ESR). PtAAP-VAS was reduced from baseline (mean [SD]: −36.8 [26.8]) and improvements in SF-36 PCS and SF-36 MCS were reported. Synovial hypertrophy, effusion and PD signal indices were reduced from baseline to Week 12. One death was reported during the study. CONCLUSIONS: Spanish patients with RA demonstrated improvements in clinical, PDUS and patient-reported outcomes over 12 weeks of CZP treatment. No new safety signals were identified, and the safety profile was in line with previous CZP studies. These results support previous clinical trial findings investigating CZP treatment for active RA


OBJETIVOS: Evaluar la eficacia y la seguridad de certolizumab pegol (CZP) en pacientes españoles con artritis reumatoide (AR). MATERIALES Y MÉTODOS: SONAR (NCT01526434), un estudio multicéntrico, observacional, prospectivo, abierto de 12 semanas. Pacientes con AR activa ≥3 meses, según criterios ACR, recibieron CZP (400mg en las semanas 0, 2 y 4, seguido de 200mg cada 2 semanas). La variable principal de eficacia fue el cambio desde el inicio (CDI) en el HAQ en la semana 12. Otras evaluaciones incluían el DAS28-VSG, la valoración del dolor (PtAAP-VAS) y el componente físico (PCS) y mental (MCS) del SF-36. La inflamación articular se estudió utilizando ecografía con Power Doppler (PDUS) midiendo derrame, hipertrofia sinovial y señal PD sinovial. Los resultados de PDUS evaluaron el CDI hasta la semana 12 en índices de hipertrofia sinovial, derrame y PD. RESULTADOS: Un total de 77/80 pacientes recibieron ≥una dosis de CZP. La reducción media en 12 semanas desde el inicio (DE) fue de −0,6 (0,6) para HAQ y de −2,2 (1,5) para DAS28-VSG. La PtAAP-VAS disminuyó desde el inicio (media [DE]: −36,8 [26,8]) y hubo mejorías en los componentes PCS y MCS del SF-36. Los índices de señales de hipertrofia sinovial, derrame y PD disminuyeron desde el inicio hasta la semana 12. Se notificó una muerte durante el estudio. CONCLUSIONES: Los pacientes españoles con AR mostraron mejoras en resultados clínicos, PDUS y notificados por el paciente durante 12 semanas de tratamiento con CZP. No hubo nuevas señales de seguridad, y el perfil de seguridad estaba en línea con estudios previos. Estos resultados respaldan los hallazgos de ensayos clínicos previos de CZP en AR


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/diagnóstico , Certolizumab Pegol/uso terapêutico , Antirreumáticos/uso terapêutico , Fator de Necrose Tumoral alfa/uso terapêutico , Estudos Prospectivos , Certolizumab Pegol/efeitos adversos , Antirreumáticos/efeitos adversos , Fator de Necrose Tumoral alfa/efeitos adversos , Ultrassonografia Doppler , Resultado do Tratamento , Estados Unidos , Espanha , Inquéritos Epidemiológicos
5.
Rev. esp. enferm. dig ; 112(8): 636-641, ago. 2020. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-199969

RESUMO

INTRODUCCIÓN: los inhibidores del factor de necrosis tumoral alfa (anti-TNF) son fármacos eficaces en el tratamiento de la colitis ulcerosa (CU) moderada-grave. Sin embargo, muchos pacientes no responden o tienen una pérdida de respuesta terapéutica durante el seguimiento. OBJETIVO: analizar los factores que determinan la respuesta clínica a los anti-TNF en la CU. MÉTODOS: estudio multicéntrico retrospectivo en 79 pacientes con CU que iniciaron tratamiento con anti-TNF entre 2009 y 2015. El criterio de valoración principal fue la remisión clínica (índice pMayo ≤ 1) a los 12 meses. Asimismo, se analizaron la remisión y respuesta clínica (índice pMayo final ≤ 3) y la retirada de corticoides a los tres, seis y 12 meses. Se realizó análisis para identificar las variables predictoras de respuesta clínica. RESULTADOS: a los 12 meses, presentó remisión y respuesta clínica el 59,2 % y el 77,8 % de los pacientes, respectivamente. Se consiguió retirar los corticoides en el 82,4 % de los pacientes. A los 12 meses, la retirada de corticoides (< 3 meses) (OR 0,06; IC 95 %: 0,01-0,24) y la respuesta clínica a los seis meses (OR 0,008; IC 95 %: 0,001-0,053) fueron factores predictivos independientes de remisión clínica. CONCLUSIÓN: en pacientes con CU activa tratados con anti-TNF, la retirada de los corticoides en los primeros tres meses y la respuesta clínica a los seis meses de iniciado el tratamiento predicen la remisión clínica de la enfermedad


No disponible


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Colite Ulcerativa/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fármacos Gastrointestinais/uso terapêutico , Infliximab/uso terapêutico , Adalimumab/uso terapêutico , Índice de Gravidade de Doença , Resultado do Tratamento , Estudos Retrospectivos , Indução de Remissão
6.
Rev. iberoam. micol ; 37(2): 41-46, abr.-jun. 2020. tab
Artigo em Inglês | IBECS | ID: ibc-195350

RESUMO

Critically ill COVID-19 patients have higher pro-inflammatory (IL-1, IL-2, IL-6, tumor necrosis alpha) and anti-inflammatory (IL-4, IL-10) cytokine levels, less CD4 interferon-gamma expression, and fewer CD4 and CD8 cells. This severe clinical situation increases the risk of serious fungal infections, such as invasive pulmonary aspergillosis, invasive candidiasis or Pneumocystis jirovecii pneumonia. However, few studies have investigated fungal coinfections in this population. We describe an update on published reports on fungal coinfections and our personal experience in three Spanish hospitals. We can conclude that despite the serious disease caused by SARS-CoV-2 in many patients, the scarcity of invasive mycoses is probably due to the few bronchoscopies and necropsies performed in these patients because of the high risk in aerosol generation. However, the presence of fungal markers in clinically relevant specimens, with the exception of bronchopulmonary colonization by Candida, should make it advisable to early implement antifungal therapy


Los pacientes gravemente enfermos con COVID-19 presentan concentraciones más elevadas de citoquinas pro-inflamatorias (IL-1, IL-2, IL-6 y factor de necrosis tumoral alfa) y anti-inflamatorias (IL-4 e IL-10), menor expresión de interferón-gama y un número más bajo de células CD4 y CD8. Esta grave situación clínica aumenta el riesgo de padecer coinfecciones fúngicas, como la aspergilosis pulmonar invasora, la candidiasis invasora o la neumonía por Pneumocystis jirovecii. Sin embargo, pocos estudios han investigado las coinfecciones fúngicas en esta población. En esta revisión describimos una actualización de las publicaciones sobre coinfecciones fúngicas en esta población de pacientes y nuestra experiencia personal en tres hospitales españoles. Podemos concluir que a pesar de la grave enfermedad causada por el SARS-CoV-2 en muchos pacientes, la baja frecuencia de micosis invasoras se debe probablemente a las pocas broncoscopias y necropsias realizadas en estos pacientes debido al alto riesgo de producción de aerosoles. Sin embargo, la presencia de marcadores fúngicos en muestras clínicas relevantes, con la excepción de la colonización broncopulmonar por Candida, debería aconsejar la instauración precoz de una terapia antifúngica


Assuntos
Humanos , Betacoronavirus , Infecções por Coronavirus/sangue , Infecções por Coronavirus/epidemiologia , Pneumonia Viral/sangue , Pneumonia Viral/epidemiologia , Candidíase Invasiva/epidemiologia , Coinfecção , Aspergilose Pulmonar Invasiva/epidemiologia , Linfócitos T CD4-Positivos , Linfócitos T CD8-Positivos , Interferon gama/sangue , Interleucinas/sangue , Fator de Necrose Tumoral alfa/sangue
8.
Nefrología (Madrid) ; 40(2): 171-179, mar.-abr. 2020. ilus, tab, graf
Artigo em Espanhol | IBECS | ID: ibc-199105

RESUMO

ANTECEDENTES: La principal causa de morbimortalidad en el paciente con enfermedad renal crónica (ERC) es la cardiovascular. La inflamación y las alteraciones en el metabolismo óseo-mineral en estos pacientes conllevan aumento del riesgo cardiovascular. OBJETIVOS: Valorar el papel de paricalcitol sobre distintos parámetros séricos relacionados con inflamación, fibrosis y enfermedad óseo-mineral en la ERC. MATERIAL Y MÉTODOS: Estudio prospectivo, no controlado en 46 pacientes con ERC estadios III-V sin diálisis, con niveles elevados de paratohormona, según su estadio de ERC, por lo que se introdujo tratamiento con el análogo de vitamina D paricalcitol. Durante 4 meses de tratamiento valoramos los parámetros clásicos y novedosos del metabolismo óseo-mineral en suero (calcio, fósforo, paratohormona, factor de crecimiento fibroblástico-23 [FGF-23], Klotho y calcidiol) y parámetros relacionados con el proceso de inflamación-fibrosis y anticalcificantes (interleucina-6 y 10, factor de necrosis tumoral alfa [TNF-a], factor de crecimiento transformante beta [TGF-b], proteína ósea morfogénica-7 [BMP-7], y fetuína-A). RESULTADOS: Tras el uso de paricalcitol los niveles de Klotho aumentaron (p = 0,001) y los de FGF-23 se mantuvieron estables al igual que los de calcio y fósforo; calcidiol aumentó de forma significativa (p = 0,010) y paratohormona descendió (p = 0,002). Los parámetros de inflamación, fibrosis y calcificación mostraron una regulación benigna con descenso significativo de interleucina-6 (p = 0,001), TNF-alfa (p = 0,005) y TGF-β (p = 0,001) y aumento de BMP-7 (p = 0,001), fetuína-A (p = 0,001) e interleucina-10 (p = 0,001). El filtrado glomerular y la proteinuria se mantuvieron estables. CONCLUSIONES: El tratamiento con paricalcitol en el paciente renal sin diálisis parece ser beneficioso en la regulación de los parámetros inflamatorios y anticalcificantes, preservando la función renal y el eje óseo-mineral. Los marcadores elegidos en nuestro estudio podrían indicarnos un efecto positivo de paricalcitol a nivel vascular


BACKWARD: Cardiovascular events are the major cause of morbidity and mortality in patients with chronic kidney disease (CKD). Inflammation and mineral-bone disorder are pathological conditions that have been associated with an increased cardiovascular risk. OBJECTIVE: Show paricalcitol regulation overinflammatory, fibrotic and mineral disorder parameters in CKD. MATERIAL AND METHODS: Prospective Study in 46 CKD stages III-V patients without dialysis patients whith elevated parathormone in which we introduced paricalcitol. We evaluated classic and newest mineral and bone metabolism serum parameters (calcium, phosphorus, parathormone, fibroblast growth factor-23 [FGF-23], Klotho, calcidiol), inflammatory-fibrosis and anticalcifying parameters (interleukin-6 and 10, tumor necrosis factor-a [TNF- alfa], transforming growth factor-b [TGF-β],bone morphogenic protein-7 [BMP-7] and fetuin-A) for four months. RESULTS: At the end of study soluble Klotho increased (p = .001), FGF-23 remained stable, calcium and phosphorus levels were not increased, calcidiol increased (p = .010) and PTH decreased (p = .002). Inflammation-fibrosis and calcification parameters showed positive regulation after paricalcitol treatment: interleukin-6 decreased significantly (p = .001) and also TNF-alfa did (p = .005), on the contrary, interleukin-10 and fetuin-A increased (p = .001 for both). Anti-fibrosis marker BMP-7 increased (p = .001) and TGF-b decreased (p = .001). We did not find significant changes in renal function. CONCLUSIONS: Paricalcitol treatment might be profitable in regulating inflammatory and anticalcificant parameters, unmodified calcium or phosphorus seric levels and preserving kidney function in renal patients with no dialysis. Our selected parameters could indicate paricalcitol effects in mineral and endothelial disorder related to renal disease


Assuntos
Humanos , Masculino , Feminino , Idoso , Conservadores da Densidade Óssea/uso terapêutico , Ergocalciferóis/uso terapêutico , Insuficiência Renal Crônica/tratamento farmacológico , Proteína Morfogenética Óssea 7/sangue , Calcifediol/sangue , Cálcio/sangue , Fatores de Crescimento de Fibroblastos/sangue , Taxa de Filtração Glomerular , Glucuronidase/sangue , Interleucina-10/sangue , Interleucina-6/sangue , Hormônio Paratireóideo/sangue , Fósforo/sangue , Estudos Prospectivos , Proteinúria/metabolismo , Insuficiência Renal Crônica/complicações , Insuficiência Renal Crônica/terapia , Fator de Crescimento Transformador beta/sangue , Fator de Necrose Tumoral alfa/sangue , Calcificação Vascular/etiologia , Calcificação Vascular/prevenção & controle , alfa-2-Glicoproteína-HS/análise
9.
Arch. med. deporte ; 37(196): 105-109, mar.-abr. 2020. graf
Artigo em Espanhol | IBECS | ID: ibc-199544

RESUMO

INTRODUCCIÓN: El ejercicio físico exhaustivo genera marcadores inflamatorios y de ácido láctico. La suplementación con sustancias naturales es motivo de análisis debido a sus escasos efectos secundarios. OBJETIVO: Determinar la respuesta inflamatoria y el nivel de ácido láctico inducidos por ejercicio físico exhaustivo después de la ingesta de soja en modelo animal. MATERIALES Y MÉTODO: Se emplearon treinta ratas macho de raza Sprawley dawley de 180 a 200 g, sanos divididos en tres grupos: sedentario (C), con ingesta de soja a prueba (E+TP) y sin ingesta de soja a prueba (E). Los grupos E+TP y E, realizaron la prueba Morris Water Maze Test. Se determinaron marcadores inflamatorios como factor de necrosis tumoral alfa (TNF-a), interleuquina 1 beta (IL-1Beta), interleuquina 6 (IL-6) en plasma mediante técnica ELISA, enzima ciclooxigenasa 2 (COX-2), óxido nítrico sintaza (iNOS) y como marcador antiinflamatorio Receptor gamma activado por proliferador de peroxisoma (PPAR-γ), el cual, se midió en músculos cuádriceps mediante técnica de Western-blot y se midió el ácido láctico en sangre. RESULTADOS: Se obtuvo una disminución significativa en plasma de los niveles inflamatorios de TNF-alfa (600 vs 350 pg/ml), IL-1Beta (450 vs 150 pg/ml), e IL-6 (480 vs 100 pg/ml), COX-2 (52 vs 25 RDU) e iNOS (58 vs 8 RDU) en el grupo E+TP en comparación con el grupo E. Además se observó un aumento de la expresión de la proteína PPAR-γ (18 vs 65 RDU) en el grupo E+TP en comparación con el grupo E. Respecto a las mediciones de ácido láctico los grupos obtuvieron valores máximos de: E:35, C:22 y E+TP:28 Mmol/Lactato, lo cual, indica que el grupo E y E+TP a pesar que se sometieron a la misma prueba, los niveles de ácido láctico son heterogéneos. CONCLUSIÓN: La ingesta de soja mitiga los niveles de ácido láctico y de marcadores inflamatorios inducidos por el ejercicio fisico exhautivo en modelo animal


INTRODUCTION: Exhautive physical exercise generates inflammatory and lactic acid markers. The supplementation with natural substances is reason for analysis due to its limited side effects. OBJECTIVE: To determine the inflammatory response and the level of lactic acid induced by exhaustive physical exercise after the ingestion of soybean in animal model. MATERIALS AND METHOD: Thirty male Sprawley dawley rats from 180 to 200 g were used, healthy divided into three groups: sedentary (C), with soybean intake tested (E+TP) and without soybean intake tested (E). The E + TP and E groups performed the Morris Water Maze Test. Inflammatory markers were determined as tumor necrosis factor alpha (TNF-a), interleukin 1 beta (IL-1β), interleukin 6 (IL-6) in plasma by ELISA technique, enzyme cyclooxygenase 2 (COX-2), nitric oxide synthase (iNOS) and as anti-inflammatory marker Peroxisome proliferator-activated receptor gamma (PPAR-γ), which was measured in quadriceps muscles by Western-blot technique and measured lactic acid in blood. RESULTS: A significant decrease in plasma was obtained in the inflammatory levels of TNF-alpha (600 vs 350 pg/ml), IL-1Beta (450 vs 150 pg/ml), and IL-6 (480 vs 100 pg/ml), COX-2 (52 vs. 25 RDU) and iNOS (58 vs. 8 RDU) in the E+TP group compared to the E group. In addition an increase in the expression of the PPAR-γ protein was observed (18 vs 65 RDU) in the group E+TP compared to group E. Regarding the measurements of lactic acid, the groups obtained maximum values of: E: 35, C: 22 and E+TP: 28 Mmol/Lactate, which indicates that Group E and E+TP although they underwent the same test, lactic acid levels are heterogeneous. CONCLUSION: The intake of soy mitigates the levels of lactic acid and inflammatory markers induced by exhautive physical exercise in animal models


Assuntos
Animais , Masculino , Ratos , Soja , Ácido Láctico/sangue , Inflamação/dietoterapia , Suplementos Nutricionais , Anti-Inflamatórios/administração & dosagem , Aprendizagem em Labirinto , Fator de Necrose Tumoral alfa , Modelos Animais de Doenças , Ratos Sprague-Dawley , Interleucina-6 , Interleucina-1beta , Peroxissomos
10.
Allergol. immunopatol ; 48(1): 48-55, ene.-feb. 2020. graf, tab
Artigo em Inglês | IBECS | ID: ibc-186591

RESUMO

Background: Several pro-inflammatory and anti-inflammatory mediators play a role in the immunopathogenesis of food allergy (FA). The aim of this study was to investigate the utility of serum biomarkers like interleukin (IL)-10, TNF-alfa, and IL-6 in the diagnosis and/or follow-up of FA. Methods: Sixty (25 females, 41.6%) newly diagnosed FA patients [IgE mediated (group-1, n = 37), non-IgE (group-2, n = 23)] with a median age of nine (1-33) months were enrolled. Twenty-four healthy children with a median age of eight (1-36) months constituted the control group (CG). In all the subjects, serum TNF-alfa, IL-6 and IL-10 levels were evaluated at the time of diagnosis and reassessed four weeks after therapeutic elimination diet (TED). Results: The mean white blood cell count and median absolute eosinophile count of the CG were significantly lower than group-1 (p values were 0.019 and 0.006, respectively). The mean absolute neutrophile count and the median IL-6 were significantly higher in group-1 when compared with group-2 (p values were 0.005 and 0.032, respectively. Median TNF-alfa and IL-6 levels were significantly higher in the pre-TED among all patients (p values were 0.005 and 0.018, respectively). In group-1, median TNF-α and IL-6 levels decreased significantly after TED (p values were 0.01 and 0.029, respectively). Conclusions: Our findings support the role of inflammation in the pathogenesis of FA. Serum TNF-alfa and IL-6 levels may be useful markers for follow-up in FA, especially among IgE-mediated FA patients. Evaluation of IL-10 results was not sufficient for an interpretation of clinical tolerance


No disponible


Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Pré-Escolar , Interleucina-10/sangue , Interleucina-6/sangue , Hipersensibilidade Alimentar/diagnóstico , Hipersensibilidade Imediata/diagnóstico , Fator de Necrose Tumoral alfa/sangue , Mucosa Intestinal/imunologia , Algoritmos , Alérgenos , Anafilaxia/imunologia , Biomarcadores , Fator de Necrose Tumoral alfa/imunologia , Fator de Necrose Tumoral alfa/análise
12.
Nefrología (Madrid) ; 40(1): 12-25, ene.-feb. 2020. ilus
Artigo em Inglês | IBECS | ID: ibc-198950

RESUMO

BACKGROUND: Drug-induced nephrotoxicity is a frequent adverse event that can lead to acute or chronic kidney disease and increase the healthcare expenditure. It has high morbidity and mortality incidence in 40-70% of renal injuries and accounts for 66% cases of renal failure in elderly population. OBJECTIVE: Amelioration of drug-induced nephrotoxicity has been long soughed to improve the effectiveness of therapeutic drugs. This study was conducted to review the melatonin potential to prevent the pathogenesis of nephrotoxicity induced by important nephrotoxic drugs. METHODS: We analyzed the relevant studies indexed in Pubmed, Medline, Scielo and Web of science to explain the molecular improvements following melatonin co-administration with special attention to oxidative stress, inflammation and apoptosis as key players of drug-induced nephrotoxicity. RESULTS: A robust consensus among researchers of these studies suggested that melatonin efficiently eradicate the chain reaction of free radical production and induced the endogenous antioxidant enzymes which attenuate the lipid peroxidation of cellular membranes and subcellular oxidative stress in drug-induced nephrotoxicity. This agreement was further supported by the melatonin role in disintegration of inflammatory process through inhibition of principle pro-inflammatory or apoptotic cytokines such as TNF-alfa and NF-κB. These studies highlighted that alleviation of drug-induced renal toxicity is a function of melatonin potential to down regulate the cellular inflammatory and oxidative injury process and to stimulate the cellular repair or defensive mechanisms. CONCLUSION: The comprehensive nephroprotection and safer profile suggests the melatonin to be a useful adjunct to improve the safety of nephrotoxic drugs


ANTECEDENTES: La nefrotoxicidad inducida por medicamentos es un acontecimiento adverso frecuente que puede conducir a una nefropatía aguda o crónica, e incrementar los costes sanitarios. Presenta una incidencia elevada de morbimortalidad en el 40-70% de las lesiones renales y es responsable del 66% de los casos de insuficiencia renal entre la población de edad avanzada. OBJETIVO: La mejora de la nefrotoxicidad inducida por medicamentos es un objetivo anhelado desde hace mucho tiempo, para mejorar la eficacia de los fármacos terapéuticos. Este estudio se llevó a cabo con el propósito de revisar el potencial de la melatonina para prevenir la patogenia de la nefrotoxicidad inducida por medicamentos nefrotóxicos importantes. MÉTODOS: Analizamos los estudios relevantes indexados en Pubmed, Medline, Scielo y Web of Science, para explicar las mejoras moleculares posteriores a la administración concomitante de melatonina; prestando especial atención al estrés oxidativo, la inflamación y la apoptosis como actores fundamentales de la nefrotoxicidad inducida por medicamentos. RESULTADOS: Un sólido consenso entre los investigadores de estos estudios sugirió que la melatonina erradica de forma eficiente la reacción en cadena de producción de radicales libres e induce las enzimas antioxidantes endógenas que atenúan la peroxidación lipídica de las membranas celulares y el estrés oxidativo subcelular en la nefrotoxicidad inducida por medicamentos. Este consenso se vio respaldado por el papel de la melatonina en la desintegración del proceso inflamatorio a través de la inhibición de las principales citocinas proinflamatorias o apoptóticas, como el TNF-α y el NF-κB. Estos estudios subrayan que la mitigación de la nefrotoxicidad inducida por medicamentos se deriva del potencial de la melatonina para regular a la baja el proceso celular de lesión inflamatoria y oxidativa, y estimular la reparación celular o los mecanismos defensivos de las células. CONCLUSIÓN: La nefroprotección exhaustiva y el perfil de seguridad más favorable sugieren que la melatonina es un complemento útil para mejorar la seguridad de los fármacos nefrotóxicos


Assuntos
Humanos , Antineoplásicos/efeitos adversos , Antioxidantes/uso terapêutico , Rim/efeitos dos fármacos , Nefropatias/induzido quimicamente , Nefropatias/tratamento farmacológico , Melatonina/uso terapêutico , Acetaminofen/administração & dosagem , Antibacterianos/efeitos adversos , Apoptose , Doença Crônica , Radicais Livres , Imunossupressores/efeitos adversos , Melatonina/metabolismo , Mitocôndrias/metabolismo , NF-kappa B/antagonistas & inibidores , Estresse Oxidativo , Fator de Necrose Tumoral alfa/antagonistas & inibidores
13.
Rev. esp. patol ; 52(4): 242-245, oct.-dic. 2019. ilus
Artigo em Espanhol | IBECS | ID: ibc-191944

RESUMO

El riesgo asociado de desarrollar una enfermedad linfoproliferativa en la enfermedad inflamatoria intestinal (EII) es un tema controvertido desde hace décadas y se discute si el riesgo se asocia a la inflamación crónica de la EII per se o a los tratamientos de la misma, especialmente los fármacos tiopurínicos (azatioprina y mercaptopurina) y los agentes anti-TNF-alfa. Presentamos un caso excepcional de un varón de 35 años diagnosticado de enfermedad de Crohn con 17 años y en tratamiento con azatioprina, que presentó años después, un linfoma de Hodgkin intestinal


The risk of developing a lymphoproliferative disease associated with inflammatory bowel disease (IBD) has been a controversial issue for decades; it is debatable whether the risk is associated with the chronic inflammation of IBD per se or its treatment, especially with thiopurine drugs (azathioprine and mercaptopurine) and anti-TNF-alfa agents. We present an unusual case of a 35-year-old man who had been diagnosed with Crohn's disease at age 17 and treated with azathioprine, presenting years later with an intestinal Hodgkin's lymphoma


Assuntos
Humanos , Masculino , Adulto , Doença de Hodgkin/tratamento farmacológico , Doenças Inflamatórias Intestinais/complicações , Doença de Crohn/patologia , Mercaptopurina/uso terapêutico , Azatioprina/uso terapêutico , Neoplasias Intestinais/patologia , Doença de Hodgkin/patologia , Transtornos Linfoproliferativos/epidemiologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores
14.
Reumatol. clín. (Barc.) ; 15(6): e108-e110, nov.-dic. 2019. ilus
Artigo em Espanhol | IBECS | ID: ibc-189664

RESUMO

Los fármacos inhibidores del factor de necrosis tumoral alfa (anti-TNF alfa) son ampliamente utilizados en diversas especialidades médicas. El principal efecto adverso de estos fármacos es el aumento del riesgo de infecciones. Presentamos el caso de un varón de 30 años con espondilitis anquilosante, en tratamiento desde hacía 2 semanas con golimumab, que consulta por lesiones asalmonadas en tronco, palmas y plantas de 10 días de evolución. Con la sospecha de un secundarismo luético se solicitaron pruebas treponémicas y no treponémicas que confirmaron el diagnóstico. Asimismo se solicitó una punción lumbar, aunque no existía sintomatología neurológica, para descartar neurosífilis. Los casos de sífilis en pacientes en tratamiento con anti-TNF alfa son excepcionales en la literatura y no hay protocolos establecidos que nos guíen sobre cómo actuar ante esta situación


Inhibitors of tumor necrosis factor-alpha (anti-TNF-alpha) are widely used in different medical specialties. The main adverse effect of these agents is the increased risk of infection. We report the case of a 30-year-old man with ankylosing spondylitis who had begun receiving golimumab two weeks earlier. He presented with a 10-day history of salmon-colored lesions on trunk, palms and soles. The clinical suspicion was secondary syphilis. Treponemal and nontreponemal tests confirmed the diagnosis of syphilis. Lumbar puncture was also performed, although there was no neurological involvement, to rule out neurosyphilis. Cases of syphilis in patients in treatment with TNF-alpha inhibitors are uncommon in the literature and there are no established protocols


Assuntos
Humanos , Masculino , Adulto , Anticorpos Monoclonais/efeitos adversos , Sífilis/induzido quimicamente , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Anticorpos Monoclonais/uso terapêutico , Espondilite Anquilosante/tratamento farmacológico
16.
Eur. j. anat ; 23(6): 405-413, nov. 2019. graf, ilus
Artigo em Inglês | IBECS | ID: ibc-185083

RESUMO

Nicotine exposure during pregnancy is linked to multiple obstetrical, fetal, and developmental complications. Parsley (Petroselinum crispum) is an aromatic herb, which has well-known potent anti-inflammatory and anti-oxidative effects. The purpose of this study was to investigate, for the first time, the protective effect of parsley extract on alveolar stage of lung development in rats exposed to perinatal nicotine. Thirty Sprague-Dawley adult female rats were randomly divided into five main groups after being pregnant: control, sham control, parsley-treated (5mg /kg/day), nicotine-treated group (1mg /kg/day), and protected (nicotine + parsley extract) groups. Nicotine was injected subcutaneously, while parsley extract was given orally by gastric tube from the 7th day of pregnancy until the 21st day postnatally. At the end of the experiment, lungs of 21-day-old male offspring were subjected to biochemical, histological, and immuno-histochemical analyses. Our results revealed toxic effects of nicotine on alveolar stage of rat lung development. These were indicated by histopathological alterations, including poorly developed primary and secondary septa; interstitial tissue infiltration with inflammatory cells, atypical features appeared in some cells of bronchioles and blood vessels. In addition, a reduction in elastic fibers contents and in alpha smooth muscle expression, an increase in surfactant protein B expression, and changes of oxidative stress indices and tumor necrosis factor alpha level in lung tissue were detected. Co-administration of parsley extract ameliorated nicotine induced toxic alterations on the development of the lung. Therefore, parsley can be a promising candidate for the prevention of nicotine-induced toxicity in the developing lung


No disponible


Assuntos
Animais , Petroselinum/efeitos dos fármacos , Pulmão/anatomia & histologia , Pulmão/efeitos dos fármacos , Nicotina/toxicidade , Estresse Oxidativo/efeitos dos fármacos , Nicotina/efeitos adversos , Ratos Sprague-Dawley , Imuno-Histoquímica , Projetos de Pesquisa , Análise de Variância , Fator de Necrose Tumoral alfa
17.
Rev. esp. enferm. dig ; 111(11): 823-827, nov. 2019. ilus, tab, graf
Artigo em Inglês | IBECS | ID: ibc-190504

RESUMO

Background and aims: to investigate the potential effect and mechanism of Salvia miltiorrhiza in Gynura segetum-induced hepatic sinusoidal obstruction syndrome (HSOS). Methods: the mice were gavaged with PBS, Gynura segetum or Gynura segetum, along with 100 or 200 mg/kg Salvia miltiorrhiza. Histological scoring and liver function were performed. The expression of tumor necrosis factor-alpha (TNF-alfa), vascular cellular adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and nuclear transcription factor P65 (NF-κBp65) were determined by reverse transcriptase polymerase chain reaction (RT-PCR) and western blot. Results: liver function were effectively improved in the Salvia miltiorrhiza groups. The levels of TNF-alfa, VCAM-1, ICAM-1 and NF-κBp65 were significantly lower in the Salvia miltiorrhiza groups than in the Gynura segetum group. Conclusions: Salvia miltiorrhiza has a therapeutic effect on Gynura segetum-induced HSOS


No disponible


Assuntos
Animais , Ratos , Salvia miltiorrhiza , Extratos Vegetais/farmacocinética , Hepatopatia Veno-Oclusiva/tratamento farmacológico , Moléculas de Adesão Celular/efeitos dos fármacos , Fator de Necrose Tumoral alfa/efeitos dos fármacos , Molécula 1 de Adesão de Célula Vascular/efeitos dos fármacos , Fator de Transcrição RelA/efeitos dos fármacos , Modelos Animais de Doenças , Hepatopatia Veno-Oclusiva/induzido quimicamente , Testes de Função Hepática/métodos , Substâncias Protetoras/análise
19.
Eur. j. anat ; 23(5): 325-332, sept. 2019. ilus, tab
Artigo em Inglês | IBECS | ID: ibc-183862

RESUMO

Liver ischemia reperfusion is induced during surgical procedures like liver transplantation and resection. Multiple mechanisms have been postulated to liver damage following liver ischemia reperfusion injury, such as oxidative stress and inflammatory reactions. The present study declares the possible mechanism of tadalafil, toward modulating the inflammatory response. Forty-eight rats were divided into 4 groups as follows; Sham group subjected to midline laparotomy only. Tadalafil group administered Tadalafil 10 mg/kg intraperitoneal 45 min before sham operation. I/R (Ischemiareperfusion) group, rats undergo 60 min of hepatic ischemia followed by 60 min of reperfusion. Tadalafil + I/R group rats undergo a similar pattern of I/ R after the treatment with Tadalafil 10 mg/kg, 45 min before ischemia. At the end of the reperfusion, the blood samples were collected for estimation of biochemical markers including liver enzymes using colorimetric assay method and serum: TNF-α (tumor necrosis factor-α), IL-6 (interleukin 6) levels, ICAM- 1 (Intercellular Adhesion Molecule-1) were measured. Tissues were evaluated by semiquantitative and morphometrical approaches. Tadalafil succeeded in restoring normal levels of liver enzymes and ameliorating the oxidative stress as evidenced by decreasing MDA and restoring reduced glutathione levels in liver tissue homogenate. Also, Tadalafil exhibits anti-inflammatory effects, as it significantly decreased the levels of TNF-α, IL6 and ICAM-1. The findings are supported by BCL-2, TNF-α immunomarkers. It is concluded that modulation of the inflammatory response might be one of the mechanisms of Tadalafil-mediated hepatoprotection, so it is recommended as an adjuvant therapy in liver surgery


No disponible


Assuntos
Animais , Ratos , Traumatismo por Reperfusão/veterinária , Estresse Oxidativo , Transplante de Fígado/veterinária , Apoptose/efeitos dos fármacos , Fator de Necrose Tumoral alfa , Tadalafila/administração & dosagem , Fígado/anatomia & histologia , Fígado/enzimologia , Injeções Intraperitoneais/veterinária , Imuno-Histoquímica
20.
Apunts, Med. esport (Internet) ; 54(203): 91-101, jul.-sept. 2019. tab, graf
Artigo em Inglês | IBECS | ID: ibc-187687

RESUMO

INTRODUCTION: The purpose of the study was to evaluate the salivary concentrations of Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNFalfa) and correlate the findings with the caries index, body mass index (BMI), potency of lower limbs (vertical jump), cardiorespiratory fitness, and risk of developing cardiovascular diseases in girls practicing volleyball. MATERIAL AND METHODS: Two studies were performed: 1) a cross-sectional study (n = 120) on the association of IL-6 and TNFalfa with the caries index, anthropometric measures, physical tests, and experience in volleyball practice; 2) longitudinal study (n = 63) on the effects of 8 weeks of training on salivary IL-6 and TNFalfa in girls with intermediate experience in volleyball and competitive girls. RESULTS: The median levels of IL-6 were 1.98 [1.55-3.11] pg/ml and TNFalfa, 0.46 [0.28-0.59] pg/ml and these did not correlate with the caries index, BMI, training volume, training practice, or cardiovascular risk. A correlation was observed between IL-6 and TNFalfa (r = 0.34; p < 0.001), IL-6 and vertical jump height (r = -0.28, p < 0.005), and TNFα and age (r = 0.33; p < 0.001). After 8 weeks of training, TNFα levels increased in the intermediate and competitive groups (p < 0.05), while IL-6 levels decreased only in the intermediate level group (p < 0.05). CONCLUSION: the median levels of IL-6 and TNFalfa did not correlate with the caries index, BMI, training volume, experience practice, or cardiovascular risk. Salivary levels of IL-6 were downmodulated in the group with intermediate experience and TNFalfa was upmodulated by training


INTRODUCCIÓN: el objetivo del estudio fue evaluar las concentraciones salivales de interleukina-6 (IL-6) y factor de necrosis tumoral alfa (TNFalfa) y correlacionarlas con el índice de caries, el índice de masa corporal (IMC), potencia muscular de miembros inferiores (salto vertical), la aptitud cardiorrespiratoria y riesgo de desarrollar enfermedades cardiovasculares en niñas que practican voleibol. MATERIAL Y MÉTODOS: se realizaron dos estudios: 1) un estudio transversal (n = 120) sobre la asociación de IL-6 y TNFalfa con índice de caries, medidas antropométricas, pruebas físicas y experiencia en la práctica de voleibol; 2) estudio longitudinal (n = 63) sobre el efecto de 8 semanas de entrenamiento em IL-6 y TNFalfa salivales en niñas con experiencia intermedia en voleibol y chicas competitivas. RESULTADOS: los niveles medianos de IL-6 fueron 1.98 [1.55 - 3.11] pg/ml y TNFalfa fue 0.46 [0.28 - 0.59] pg/ml y no se correlacionaron con el índice de caries, el IMC, el volumen de entrenamiento, la práctica de entrenamiento y el riesgo cardiovascular. Se observó una correlación entre IL-6 y TNFalfa (r = 0.34; p < 0.001), IL-6 y altura de salto vertical (r = -0.28, p < 0.005), y TNFalfa y edad (r = 0.33; p < 0.001). Después de 8 semanas de entrenamiento, los niveles de TNFalfa aumentaron en los grupos intermedios y competitivos (p < 0.05), mientras que los niveles de IL-6 disminuyeron solo en el grupo intermedio (p < 0.05). CONCLUSIÓN: los niveles medianos de IL-6 y TNFalfa no se correlacionaron con el índice de caries, el IMC, el volumen de entrenamiento, la experiencia práctica y el riesgo cardiovascular. Los niveles salivales de IL-6 se modificaron a la baja en el grupo con experiencia intermedia y el TNFα se moduló al alza mediante el entrenamiento


Assuntos
Humanos , Feminino , Criança , Adolescente , Interleucina-6/análise , Fator de Necrose Tumoral alfa/análise , Voleibol/fisiologia , Cárie Dentária/diagnóstico , Índice de Massa Corporal , Força Muscular/fisiologia , Perna (Membro)/fisiologia , Biomarcadores/análise , Estudos Transversais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...